CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Arizona Tribune - CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM ET in New York City. CASI will also host one-on-one meetings with investors at the conference.

Text size:

A live webcast of the fireside chat will be available on the CASI Pharmaceuticals website at www.casipharmaceuticals.com under the "Investors" tab. A replay of the webcast will be available for 90 days after the live event.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) and plans to initiate the study in third quarter of 2025.

More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT:

Ingrid Choong, PhD
650-619-6115
[email protected]

SOURCE: CASI Pharmaceuticals

View the original press release on ACCESS Newswire

T.Perez--AT

CMSC	0.22%	22.37	$
RBGPF	-0.87%	60.61	$
BCC	5.16%	74.66	$
NGG	-1.56%	79.44	$
GSK	-2.92%	50.67	$
BTI	-0.98%	58.91	$
RYCEF	-0.16%	18.4	$
RIO	-2.59%	100.08	$
BCE	0%	23.28	$
CMSD	0%	22.29	$
AZN	-1.69%	174.93	$
JRI	0.39%	12.67	$
VOD	-1.61%	14.3	$
RELX	-2.66%	31.18	$
BP	-2.66%	39.1	$

Arizona Tribune - CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Featured

J-Bay: S.Africa's surf mecca missing out on the global tour

Slimy beans: Japanese natto disgusts and delights the world

InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 22

Swiss US-Iran talks venue a playground of world leaders, movie stars